ANA-ENA, LIA 12 IgG at Test Zone Diagnostic Center

ANA-ENA, LIA 12 IgG at Test Zone Diagnostic Center

The diagnosis of systemic autoimmune rheumatic diseases (SARD) presents a significant clinical challenge due to the overlapping symptomatic presentations of various conditions. Autoimmune disorders occur when the body’s adaptive immune system loses self-tolerance, leading to the production of autoantibodies that target healthy cellular components. Among the most critical biomarkers for these conditions are antinuclear antibodies (ANA), which target substances within the cell nucleus. While a standard ANA screening test can identify the presence of these autoantibodies, it cannot specify which exact nuclear antigens are being targeted. To address this diagnostic need, Test Zone Diagnostic Center offers the ANA-ENA, LIA 12 IgG test, a highly sophisticated, multiplexed laboratory investigation that simultaneously detects twelve distinct IgG autoantibodies directed against extractable nuclear antigens (ENA) and other nuclear targets.

This advanced diagnostic panel utilizes Line Immunoassay (LIA) technology, a state-of-the-art membrane-based enzyme immunoassay. The LIA strip is coated with highly purified, recombinant, or native antigens in parallel lines. When a patient’s serum sample is applied, any specific IgG autoantibodies present will bind to their corresponding antigen lines. Through a series of highly controlled incubation, washing, and enzymatic reaction steps, visible bands develop on the strip. The intensity of these bands corresponds to the concentration of the specific autoantibodies, providing both qualitative and semi-quantitative insights. This multiplex approach is invaluable for evaluating systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren’s syndrome, systemic sclerosis (scleroderma), and inflammatory myopathies, offering clinicians a comprehensive molecular profile to guide therapeutic decisions.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the ANA-ENA, LIA 12 IgG blood test is straightforward, but adhering to clinical guidelines ensures the highest level of diagnostic accuracy. Patients should observe the following preparation steps:

• No Fasting Required: Fasting is generally not mandatory for this specific immunological test. Patients can eat and drink normally prior to the blood draw, unless otherwise instructed by their referring physician for concurrent tests.
• Hydration: Adequate hydration is highly recommended. Drinking plenty of water before the procedure makes the veins more accessible, facilitating a smoother and quicker venipuncture process.
• Medication Disclosure: It is crucial to inform the healthcare provider and laboratory staff of all current medications. Immunosuppressive drugs, systemic corticosteroids, and biologic therapies can suppress the immune response and potentially lower autoantibody titers, which may influence the interpretation of the results.
• Avoid Strenuous Exercise: Patients should avoid unusually strenuous physical activity immediately before the test to ensure baseline physiological conditions.
• No Special Dietary Restrictions: There are no specific dietary restrictions associated with this test, but maintaining a standard, balanced diet is recommended.

During the Procedure

The collection of the blood sample for the ANA-ENA, LIA 12 IgG test is a routine, minimally invasive procedure performed by highly trained phlebotomists at Test Zone Diagnostic Center. The process is designed to maximize patient comfort and ensure sample integrity:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair. The arm is extended and supported to ensure stability during the blood draw.
• Site Selection and Sanitization: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa of the arm. The skin over the selected site is thoroughly sanitized using an antiseptic swab (usually 70% isopropyl alcohol) to prevent contamination.
• Tourniquet Application: A sterile tourniquet is applied a few inches above the selected site to temporarily restrict venous blood flow, making the vein more prominent and easier to access.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection tube (typically a serum separator tube with a gold or red top) is gently inserted into the vein. Patients may feel a brief, mild pinch or prick.
• Sample Collection: The required volume of blood (usually 3 to 5 milliliters) is drawn into the tube. Once the collection is complete, the tourniquet is released, and the needle is carefully withdrawn.
• Post-Draw Care: Immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to promote hemostasis. A small adhesive bandage is applied to keep the site clean.
• Sample Processing: The collected blood sample is allowed to clot naturally at room temperature before being centrifuged. Centrifugation separates the liquid serum from the cellular components. The isolated serum, containing the IgG autoantibodies, is then processed using the Line Immunoassay platform under strict quality-controlled laboratory conditions.

When is a ANA-ENA, LIA 12 IgG Performed?

Evaluation of Suspected Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus is a multi-system autoimmune disease characterized by widespread inflammation and tissue damage. Physicians frequently request the ANA-ENA, LIA 12 IgG panel when a patient presents with classic symptoms of SLE, such as a malar (butterfly) rash across the cheeks and nose, photosensitivity, unexplained prolonged fevers, joint pain, and chronic fatigue. The test is essential for identifying highly specific markers like anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) antibodies, which are key diagnostic criteria for SLE and help differentiate it from other connective tissue disorders.

Investigation of Sjögren’s Syndrome

Sjögren’s syndrome is a chronic autoimmune disorder primarily affecting the exocrine glands, leading to severe dryness of the eyes (keratoconjunctivitis sicca) and mouth (xerostomia). It can also cause systemic manifestations affecting the joints, kidneys, and lungs. When patients present with persistent dry eyes, dry mouth, salivary gland enlargement, or unexplained dental decay, clinicians order the ANA-ENA, LIA 12 IgG test. The panel specifically evaluates the presence of anti-SS-A (Ro) and anti-SS-B (La) antibodies, which are hallmark immunological markers for Sjögren’s syndrome, aiding in its definitive diagnosis.

Diagnosis of Systemic Sclerosis (Scleroderma)

Systemic Sclerosis, commonly known as scleroderma, is a rare autoimmune disease characterized by abnormal collagen deposition, leading to the thickening and hardening of the skin and internal organs. Symptoms often begin with Raynaud’s phenomenon (color changes in fingers and toes in response to cold) and joint stiffness. The ANA-ENA, LIA 12 IgG panel is requested to detect anti-Scl-70 (anti-topoisomerase I) and anti-Centromere B antibodies. Anti-Scl-70 is strongly associated with diffuse cutaneous systemic sclerosis and interstitial lung disease, while anti-Centromere B is a marker for limited cutaneous systemic sclerosis (formerly CREST syndrome), helping clinicians classify the disease subtype and assess prognosis.

Assessment of Mixed Connective Tissue Disease (MCTD)

Mixed Connective Tissue Disease is an overlap syndrome that combines clinical features of SLE, systemic sclerosis, and polymyositis. Patients often present with swollen hands, joint pain, Raynaud’s phenomenon, and muscle weakness. Because the symptoms overlap significantly with other diseases, diagnosing MCTD is challenging. The ANA-ENA, LIA 12 IgG test is critical in this scenario because it detects anti-nRNP/Sm (U1-RNP) antibodies. High titers of anti-U1-RNP antibodies, in the absence of other lupus-specific antibodies, are the defining immunological feature required for the diagnosis of MCTD.

Investigation of Inflammatory Myopathies

Inflammatory myopathies, including polymyositis and dermatomyositis, are characterized by chronic muscle inflammation, progressive proximal muscle weakness, and, in dermatomyositis, distinctive skin rashes (such as the heliotrope rash and Gottron’s papules). When patients present with difficulty climbing stairs, rising from a chair, or lifting objects, accompanied by elevated muscle enzymes, the ANA-ENA, LIA 12 IgG panel is ordered. It screens for anti-Jo-1 (histidyl-tRNA synthetase) and anti-PM-Scl antibodies. The presence of anti-Jo-1 is highly specific for antisynthetase syndrome, a subset of inflammatory myopathy associated with interstitial lung disease, arthritis, and Raynaud’s phenomenon.

What Does a ANA-ENA, LIA 12 IgG Detect?

The ANA-ENA, LIA 12 IgG panel at Test Zone Diagnostic Center is designed to detect twelve clinically significant IgG autoantibodies. Each of these antibodies targets a specific cellular component, and their presence provides critical diagnostic clues:

• Anti-dsDNA (double-stranded DNA): Highly specific for Systemic Lupus Erythematosus (SLE). Its levels often fluctuate with disease activity, making it useful for monitoring lupus nephritis and disease flares.
• Anti-Sm (Smith): An antibody directed against core proteins of small nuclear ribonucleoproteins. It is highly specific for SLE and is included in the classification criteria for the disease.
• Anti-nRNP/Sm (U1-RNP): Targets the U1 ribonucleoprotein complex. High levels are diagnostic for Mixed Connective Tissue Disease (MCTD), though it can also be found in SLE.
• Anti-SS-A (Ro-60): Targets a 60 kDa ribonucleoprotein. It is strongly associated with Sjögren’s syndrome, SLE, and is linked to neonatal lupus and congenital heart block.
• Anti-SS-A (Ro-52): Targets a 52 kDa E3 ubiquitin ligase. While often found alongside Ro-60, it is also associated with inflammatory myopathies and systemic sclerosis.
• Anti-SS-B (La): Targets a 48 kDa transcription termination factor. It is highly associated with Sjögren’s syndrome and is almost always found in conjunction with anti-SS-A.
• Anti-Scl-70 (Topoisomerase I): Targets DNA topoisomerase I. It is a specific marker for diffuse cutaneous systemic sclerosis and indicates a higher risk for pulmonary fibrosis.
• Anti-PM-Scl: Targets the exosome complex. It is a marker for polymyositis/systemic sclerosis overlap syndrome, indicating a generally favorable prognosis compared to other subtypes.
• Anti-Jo-1 (Histidyl-tRNA synthetase): The most common myositis-specific autoantibody. It is diagnostic for antisynthetase syndrome, characterized by myositis, interstitial lung disease, and arthritis.
• Anti-Centromere B: Targets centromere-associated proteins. It is highly specific for limited cutaneous systemic sclerosis (CREST syndrome) and is associated with a lower risk of severe pulmonary fibrosis.
• Anti-Histone: Targets chromatin histone proteins. While present in idiopathic SLE, it is highly characteristic of drug-induced lupus erythematosus, often triggered by medications like hydralazine or procainamide.
• Anti-Nucleosome: Targets the nucleosome complex (DNA-histone complexes). It is a sensitive marker for SLE and is strongly correlated with active lupus nephritis and renal involvement.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely and accurate results are essential for effective clinical management. The ANA-ENA, LIA 12 IgG test is a complex, multi-step immunological assay that requires meticulous handling and precise calibration. Our state-of-the-art laboratory utilizes automated processing systems to ensure maximum reproducibility and eliminate human error. Each run is subjected to rigorous internal quality control protocols, and results are verified by experienced consultant pathologists before release.

The typical turnaround time for the ANA-ENA, LIA 12 IgG panel is 24 to 48 hours from the time of sample collection. Patients and referring physicians can access reports securely online through the Test Zone Diagnostic Center web portal or mobile application. Additionally, physical copies of the reports can be collected directly from our main center or designated collection points. Patients are notified via SMS as soon as their verified results are ready for download.

ANA-ENA, LIA 12 IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA IgG	Negative / Non-reactive	Positive (Highly specific for SLE; correlates with active lupus nephritis)
Anti-Sm IgG	Negative / Non-reactive	Positive (Highly specific for SLE; diagnostic marker)
Anti-nRNP/Sm IgG	Negative / Non-reactive	Positive (Diagnostic for Mixed Connective Tissue Disease; also seen in SLE)
Anti-SS-A (Ro-60/Ro-52) IgG	Negative / Non-reactive	Positive (Strongly associated with Sjögren’s syndrome, SLE, and neonatal lupus)
Anti-SS-B (La) IgG	Negative / Non-reactive	Positive (Associated with Sjögren’s syndrome and SLE; usually co-exists with anti-SS-A)
Anti-Scl-70 IgG	Negative / Non-reactive	Positive (Specific for diffuse cutaneous systemic sclerosis; risk of pulmonary fibrosis)
Anti-Jo-1 IgG	Negative / Non-reactive	Positive (Diagnostic for antisynthetase syndrome and inflammatory myopathies)
Anti-Centromere B IgG	Negative / Non-reactive	Positive (Associated with limited cutaneous systemic sclerosis / CREST syndrome)
Anti-Histone IgG	Negative / Non-reactive	Positive (Highly associated with drug-induced lupus and idiopathic SLE)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for ANA-ENA, LIA 12 IgG?

• Experienced healthcare professionals: Our laboratory is staffed by highly trained medical technologists and supervised by experienced consultant pathologists specializing in immunology and serology.
• Patient-focused care: We prioritize patient comfort and convenience, offering a seamless experience from registration and blood collection to report delivery.
• Quality diagnostic services: Test Zone Diagnostic Center adheres to international quality standards, utilizing certified reagents and participating in external quality assurance programs.
• Professional reporting: Our diagnostic reports are comprehensive, clear, and structured to provide maximum clinical utility for referring physicians.
• Modern diagnostic approach: We utilize state-of-the-art automated Line Immunoassay (LIA) platforms to ensure high sensitivity, specificity, and reproducibility of results.
• Comfortable environment: Our collection centers are designed to provide a hygienic, calm, and welcoming atmosphere for all patients.
• Convenient location: Strategically located to ensure easy accessibility for patients requiring advanced diagnostic investigations.
• Commitment to accurate diagnosis: We are dedicated to delivering precise, evidence-based diagnostic insights that form the foundation of successful clinical management.